fevipiprant

Known as: 1-(4-methanesulfonylbenzyl)-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
012320152017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Dose-related efficacy and safety of fevipiprant (QAW039), an oral DP2 (CRTh2) receptor antagonist, was assessed in patients with… (More)
Is this relevant?
2017
2017
Further optimization of an initial DP2 receptor antagonist clinical candidate NVP-QAV680 led to the discovery of a follow-up… (More)
  • table 1
  • table 2
  • figure 1
  • table 5
  • table 3
Is this relevant?
2017
2017
Fevipiprant is a novel oral prostaglandin D2 receptor 2 (DP2; also known as CRTh2) antagonist, which is currently in development… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2016
2016
BACKGROUND Eosinophilic airway inflammation is often present in asthma, and reduction of such inflammation results in improved… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2016
2016
Here we describe the pharmacologic properties of a series of clinically relevant chemoattractant receptor-homologous molecules… (More)
  • table 2
  • table 3
Is this relevant?
2016
2016
We evaluated the pharmacokinetics (PK), safety, and tolerability of a novel oral CRTh2 antagonist, fevipiprant (QAW039), in… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2016
2016
This article contains data on clinical endpoints (Peak Flow Expiratory Rate, fractional exhaled nitric oxide and total IgE serum… (More)
  • table 2
  • table 3
  • table 4
  • table 5
  • table 6
Is this relevant?
2015
2015
The synthesis of a triple tritiated isotopologue of the CRTh2 antagonist NVP-QAW039 (fevipiprant) with a specific activity >3 TBq… (More)
Is this relevant?